Polar Capital Holdings’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Polar Capital Holdings’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-377,728	Closed	-$8.18K	–	401
2022 Q3	$8.18K	Sell	377,728 -572,423	-60%	-$15.7M	0.05%	206
2022 Q2	$26.7K	Buy	950,151 +580,822	+157%	+$15.4M	0.16%	119
2022 Q1	$17K	Hold	369,329	–	–	0.08%	181
2021 Q4	$31K	Sell	369,329 -148,383	-29%	-$11.5M	0.12%	135
2021 Q3	$34.5K	Buy	517,712 +35,154	+7%	+$2.03M	0.14%	130
2021 Q2	$25.7K	Buy	482,558 +32,558	+7%	+$1.74M	0.11%	147
2021 Q1	$19.5M	Buy	450,000 +225,000	+100%	+$9.69M	0.12%	160
2020 Q4	$11.7M	Buy	+225,000	New	+$10.1M	0.07%	200

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Polar Capital Holdings's ZNTL Position: Q4 2022 in Review

Polar Capital Holdings sold out of Zentalis Pharmaceuticals (ZNTL) in Q4 2022, closing a stake of 377,728 shares — an estimated $8.18K sold.

Polar Capital Holdings first reported a position in ZNTL in Q4 2020 and held it in 8 quarters. The position peaked at $19.5M in Q1 2021. 106 funds tracked by Wall St. Rank hold ZNTL as of Q4 2022.

Polar Capital Holdings reported no remaining Zentalis Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Polar Capital Holdings sold 377,728 Zentalis Pharmaceuticals shares in Q4 2022, an estimated $8.18K.
Polar Capital Holdings first reported a position in Zentalis Pharmaceuticals in Q4 2020 and held it in 8 quarters.
Polar Capital Holdings's Zentalis Pharmaceuticals position peaked at $19.5M in Q1 2021.
106 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q4 2022.

Based on Polar Capital Holdings's 13F filing for Q4 2022, filed 14 Feb 2023.